Novocure (NASDAQ:NVCR) shares dropped 10% after the company reported that its Phase 3 TRIDENT trial failed to achieve its primary objective of demonstrating a statistically significant improvement in overall survival for patients with newly diagnosed glioblastoma.
The results disappointed investors who had been looking for evidence that earlier use of the company’s Tumor Treating Fields (TTFields) therapy could extend survival outcomes in one of the most aggressive forms of brain cancer.
Trial Evaluated Earlier Use of TTFields Therapy
The TRIDENT study was designed to assess whether starting TTFields therapy during chemoradiation treatment could improve outcomes compared with initiating the therapy later during the maintenance phase.
A total of 981 patients were enrolled and randomized shortly after surgery.
In the intent-to-treat population, patients in the Early Start Arm achieved a median overall survival of 17.7 months, compared with 17.5 months for patients who began treatment during the maintenance phase.
The study reported a hazard ratio of 0.953 and a p-value of 0.519, meaning the difference between the two groups was not statistically significant.
Primary Endpoint Not Achieved
While survival outcomes were broadly similar between the two treatment groups, the trial did not meet its primary endpoint of demonstrating a meaningful improvement in overall survival through earlier intervention.
The findings suggest that initiating TTFields therapy at the start of chemoradiation did not provide a measurable survival advantage over the current treatment approach.
The outcome represents a setback for Novocure’s efforts to further expand the clinical benefits of its technology in glioblastoma.
Safety Profile Remains Consistent
Despite missing its primary goal, the study confirmed that earlier use of TTFields therapy was both feasible and well tolerated.
Novocure reported no new safety concerns during the trial, with device-related adverse events remaining consistent with previous clinical studies involving TTFields therapy.
The company said the safety profile observed in TRIDENT aligned with the established experience of using the treatment in glioblastoma patients.
Long-Term Survival Outcomes Similar Across Both Groups
The survival data showed only modest differences between the two study arms.
In the Early Start Arm, one-year, two-year and three-year survival rates were 70.9%, 33.9% and 22.5%, respectively.
For patients in the Maintenance Start Arm, survival rates were 72.0%, 31.6% and 18.4%.
Although the early treatment group demonstrated slightly higher survival rates at the longer-term milestones, the differences were insufficient to achieve statistical significance.
Patient Characteristics Reflect Typical Glioblastoma Population
The median age of participants enrolled in the trial was 60 years.
Among the patient population, 38% had a Karnofsky Performance Status (KPS) score of 70 or 80, while 39% had a methylated MGMT promoter, a biomarker often associated with improved treatment response.
Approximately 5% of participants had IDH-mutant tumors.
The company also noted that roughly one-quarter of patients in both treatment groups did not proceed to the maintenance phase of therapy.
Results Headed to Major Oncology Conference
Novocure said the TRIDENT findings have been accepted for presentation at the 2026 Annual Meeting of the American Society for Radiation Oncology.
The presentation is expected to provide clinicians and researchers with a more detailed review of the study’s findings and their implications for future treatment strategies in glioblastoma.
While the trial reinforced the safety and feasibility of early TTFields use, investors focused on the failure to achieve the primary survival endpoint, driving a sharp decline in the company’s share price.